"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.
Emesis or gastric lavage. Slow intravenous administration of physostigmine in doses of 1 to 4 mg (0.5 to 1 mg in children) repeated as needed in one to two hours to reverse severe antimuscarinic symptoms.Administration of small doses of diazepam to control excitement and seizures.Artificial respiration with oxygen if needed for respiratory depression.Adequate hydration. Symptomatic treatment as necessary.
Risk-benefit should be considered when the following medical problems exist: glaucoma, urinary bladder neck obstruction, pyloric or duodenal obstruction or cardiospasm. Hypersensitivity to any of the ingredients.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 8/8/2008
Additional Prosed DS Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.